Tiziana Seeks Orphan Drug Status for Intranasal Foralumab in MSA…

Event summary

Tiziana Life Sciences submitted an Orphan Drug Designation request to the FDA for intranasal foralumab to treat Multiple System Atrophy (MSA).
MSA is a rare neurodegenerative disorder with no FDA-approved disease-modifying therapies, affecting approximately 0.6 per 100,000 person-years in the U.S.
The Phase 2a open-label clinical trial (NCT06868628) is ongoing at Brigham and Women’s Hospital, led by Vikram Khurana, MD, PhD.
Foralumab is a fully human anti-CD3 monoclonal antibody administered via nasal spray, targeting neuroinflammation and microglial activation.

The big picture

Tiziana’s move to seek Orphan Drug Designation for intranasal foralumab in MSA underscores the strategic importance of targeting rare neurodegenerative diseases with high unmet medical needs. The FDA’s decision will be critical, as Orphan Drug Designation could accelerate development timelines and reduce costs. The biotech sector is increasingly focused on immunomodulation therapies, particularly those that offer non-systemic delivery methods to minimize side effects.

What we're watching

Regulatory Approval: Whether the FDA grants Orphan Drug Designation within the 90-day review period, which would provide market exclusivity and other benefits.
Clinical Trial Outcomes: The results of the Phase 2a trial assessing microglial activation and clinical outcomes in MSA patients.
Market Potential: The pace at which Tiziana can advance intranasal foralumab through subsequent clinical phases given the current lack of approved therapies for MSA.